1 week Ago By Defense World Staff
JPMorgan Chase & Co. grew its stake in shares of LeMaitre Vascular, Inc. ( NASDAQ:LMAT – Free Report ) by 45.
9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 147,489 shares of the medical instruments supplier’s stock after acquiring an additional 46,430 shares during the quarter. JPMorgan Chase & Co.
owned about 0.66% of LeMaitre Vascular worth $13,590,000 at the end of the most recent quarter. Several other large investors have also modified their holdings of LMAT.
EntryPoint Capital LLC raised its position in shares of LeMaitre Vascular by 58.2% in the 4th quarter. EntryPoint Capital LLC now owns 4,440 shares of the medical instruments supplier’s stock worth $409,000 after buying an additional 1,633 shares during the period.
Segall Bryant & Hamill LLC purchased a new position in shares of LeMaitre Vascular in the 4th quarter worth about $5,446,000. Congress Wealth Management LLC DE raised its holdings in shares of LeMaitre Vascular by 3.9% in the 4th quarter.
Congress Wealth Management LLC DE now owns 114,088 shares of the medical instruments supplier’s stock worth $10,512,000 after purchasing an additional 4,279 shares during the period. Bridge City Capital LLC lifted its stake in shares of LeMaitre Vascular by 7.3% in the 4th quarter.
Bridge City Capital LLC now owns 94,471 shares of the medical instruments supplier’s stock valued at $8,705,000 after purchasing an additional 6,430 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of LeMaitre Vascular during the 4th quarter worth about $811,000. 84.
64% of the stock is currently owned by hedge funds and other institutional investors. Analysts Set New Price Targets A number of brokerages have commented on LMAT. Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th.
Lake Street Capital upped their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, February 28th.
Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective on the stock.
Finally, Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.
com, the stock has an average rating of “Moderate Buy” and an average target price of $95.25. LeMaitre Vascular Stock Up 1.
8 % Shares of NASDAQ:LMAT opened at $82.82 on Friday. The company has a market cap of $1.
87 billion, a P/E ratio of 45.26, a price-to-earnings-growth ratio of 2.22 and a beta of 0.
89. The company’s fifty day moving average is $89.17 and its two-hundred day moving average is $93.
72. LeMaitre Vascular, Inc. has a 12-month low of $62.
39 and a 12-month high of $109.58. LeMaitre Vascular ( NASDAQ:LMAT – Get Free Report ) last announced its quarterly earnings data on Thursday, February 27th.
The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts’ consensus estimates of $0.49.
LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%.
The firm had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million.
Equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.
LeMaitre Vascular Increases Dividend The company also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a $0.20 dividend.
This represents a $0.80 annualized dividend and a yield of 0.97%.
The ex-dividend date of this dividend was Thursday, March 13th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16.
LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%. Insiders Place Their Bets In other LeMaitre Vascular news, insider Trent G.
Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.
08. Following the sale, the insider now owns 5,564 shares in the company, valued at $456,915.68.
The trade was a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link .
Company insiders own 10.79% of the company’s stock. LeMaitre Vascular Company Profile ( Free Report ) LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide.
It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. Read More Five stocks we like better than LeMaitre Vascular Investing in Travel Stocks Benefits Robinhood Strategies Could Be a Game-Changer for Young Investors Stock Market Sectors: What Are They and How Many Are There? Are These 3 Retail Stocks Oversold or Really in Trouble? Energy and Oil Stocks Explained IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter .
.
